Achilles Therapeutics : Results of Annual General Meeting (Form 6-K)
June 28, 2021 at 10:46 pm EDT
Share
Results of Annual General Meeting
On June 28, 2021, Achilles Therapeutics plc ('Achilles' or the 'Company') held its 2021 Annual General Meeting (the 'Annual General Meeting'), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on May 26, 2021 were duly proposed and passed on a poll.
The matters presented for a vote and the related results are as follows:
Ordinary Resolutions
For
Against
Abstain
To re-elect Edwin Moses as a Director of the Company.
12,619,059
2,053,592
11,086,954
To re-elect Iraj Ali as a Director of the Company.
14,672,622
29
11,086,954
To re-elect Carsten Boess as a Director of the Company.
14,488,545
184,106
11,086,954
To re-elect Derek DiRocco as a Director of the Company.
14,523,077
149,574
11,086,954
To re-elect Michael Giordano as a Director of the Company.
14,638,142
34,509
11,086,954
To re-elect Julie O'Neill as a Director of the Company.
14,672,522
129
11,086,954
To re-appoint KPMG LLP as UK statutory auditors of the Company, to hold office until the conclusion of the next Annual General Meeting.
13,078,116
1,814
12,679,675
To authorize the Company's Audit Committee to determine the Company's auditors' remuneration for the fiscal year ending December 31, 2021.
12,571,946
467,191
12,720,468
Special Resolutions
For
Against
Abstain
To amend the Company's Articles of Association by deleting article 11.4(a) in its entirety and replacing it with the following new article 11.4(a):
'11.4(a) convert the Conversion Shares into Ordinary Shares and the holders of the Company's A Ordinary Shares will be deemed to have consented to such Conversion in accordance with section 630(2)(a) of the Act; and'
14,670,761
179
11,088,665
The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on May 26, 2021 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on May 26, 2021.
Attachments
Original document
Permalink
Disclaimer
Achilles Therapeutics plc published this content on 28 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 June 2021 02:45:03 UTC.
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
ACHILLES THERAPEUTICS PLC 
